No abstract

No abstract

TDF showed a favorable tolerability profile and induced rapid and sustained suppression of HBV DNA in patients with CHB treated for up to 3 years in routine clinical practice, irrespective of treatment history. Efficacy and safety in this heterogeneous patient population were consistent with data from clinical trials.

A German real world NAFLD cohort Standard of care intervention Highlights This is the first report on NAFLD from a secondarycare real-world cohort in Germany. In this outpatient cohort, diagnostics rely heavily on non-invasive surrogate scores and elastography to stage NAFLD. Every 10th patient presents with advanced fibrosis at baseline. Management of NAFLD in Germany consists predominantly of general lifestyle recommendations and best supportive care. The study underlines the applicability of noninvasive tests to identify patients at risk of advanced fibrosis in secondary care in Germany. Lay summary FLAG is a real-world cohort study that examined the liver disease burden in secondary and tertiary care. Herein, 10% of patients referred to secondary care for NAFLD exhibited advanced liver disease, whilst 64% had no significant liver scarring. These findings underline the urgent need to define patient referral pathways for suspected liver disease.

No abstract